ERBB2 and breast cancer: Although alpelisib did not show survival benefits when given in ER+ HER2– BC, its usage with trastuzumab is being tested in the ALPHABET trial in advanced HER2+ BC and could provide insights about their adjunct effect in patients with PI3KCA mutations [170].